IMRN
NASDAQ
$1.13
Immuron Ltd (IMRN)
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immunomodulated diseases in Australia, the United States and internationally. The company is headquartered in Carlton, Australia.
Sector:
Healthcare
Industry:
Biotechnology
Target: $3.91 (+246.37%)
Market Cap
$8.15M
Revenue 5Y CAGR
+38.57%
Free Cash Flow Yield
-75.74%
Beta (5Y)
0.74
Price Chart
Valuation
Market Cap$8.15M
P/S1.34
P/B1.11
Profitability
Total Revenue (TTM)$8.70M
Gross Profit (TTM)$3.18M
EBITDA-$6.06M
Profit Margin-45.9%
Operating Margin-55.1%
EPS-$0.91
Financial Health
Free Cash Flow Yield-75.74%
Growth & Risk
EPS 5Y CAGR-11.08%
Revenue 5Y CAGR+38.57%
FCF 5Y CAGR+13.79%
Beta (5Y)0.74
Sharpe Ratio-0.20